AIM ImmunoTech (NYSEAMERICAN:AIM) Given New $9.00 Price Target at Ascendiant Capital Markets

AIM ImmunoTech (NYSEAMERICAN:AIM) had its target price lowered by equities research analysts at Ascendiant Capital Markets from $10.00 to $9.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Separately, Zacks Research downgraded shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $9.00.

AIM ImmunoTech Price Performance

NYSEAMERICAN:AIM opened at $0.41 on Monday. AIM ImmunoTech has a one year low of $0.21 and a one year high of $20.35. The company has a market cap of $5.94 million, a P/E ratio of -0.06 and a beta of 1.18. The firm’s fifty day moving average price is $0.51 and its two-hundred day moving average price is $0.96. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.01.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.69) EPS for the quarter. The business had revenue of $0.02 million for the quarter. Equities analysts expect that AIM ImmunoTech will post -1.47 earnings per share for the current year.

Hedge Funds Weigh In On AIM ImmunoTech

Several hedge funds and other institutional investors have recently made changes to their positions in the company. DRW Securities LLC raised its position in shares of AIM ImmunoTech by 60.6% in the 4th quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after buying an additional 26,254 shares in the last quarter. Sabby Management LLC acquired a new position in shares of AIM ImmunoTech in the 3rd quarter valued at approximately $79,000. Finally, Corient Private Wealth LLC acquired a new position in shares of AIM ImmunoTech in the 2nd quarter valued at approximately $87,000. 12.02% of the stock is currently owned by institutional investors and hedge funds.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.